The French Pompe registry. Baseline characteristics of a cohort of 126 patients with adult Pompe disease

Revue Neurologique

Volumn 169, Issue 8-9, 2013, Pages 595-602

  Laforet P ^a   Laloui, K ^a   Granger, B ^a   Hamroun, D ^b   Taouagh, N ^a   Hogrel, J Y ^a   Orlikowski, D ^c   Bouhour, F ^d   Lacour, A ^e   Salort Campana, E ^f   Penisson Besnier, I ^g   Sacconi, S ^h   Zagnoli, F ⁱ   Chapon, F ^j   Eymard, B ^a   Desnuelle, C ^h   Pouget, J ^f  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b HÔPITAL ARNAUD DE VILLENEUVE   (France)

^c RAYMOND POINCARÉ HOSPITAL   (France)

^d HÔPITAL NEUROLOGIQUE   (France)

^e LILLE UNIVERSITY HOSPITAL   (France)

^f AIX MARSEILLE UNIVERSITY   (France)

^g ANGERS UNIVERSITY HOSPITAL   (France)

^h CENTRE HOSPITALIER UNIVERSITAIRE DE NICE   (France)

ⁱ Military Teaching Hospital Clermont Tonnerre   (France)

^j CAEN UNIVERSITY HOSPITAL   (France)

more..

Author keywords

Acid alpha glucosidase deficiency; Pompe disease; Pompe registry

Indexed keywords

GLUCAN 1,4 ALPHA GLUCOSIDASE; RECOMBINANT GLUCAN 1,4 ALPHA GLUCOSIDASE;

ADULT; ALLELE; ARTICLE; ASSISTED VENTILATION; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; DISEASE REGISTRY; FEMALE; FRANCE; GENE MUTATION; GLYCOGEN STORAGE DISEASE TYPE 2; HUMAN; HUMAN TISSUE; LIMB WEAKNESS; MALE; MOLECULAR DIAGNOSIS; MUSCLE BIOPSY; WALKER;

ACID ALPHA-GLUCOSIDASE DEFICIENCY; DÉFICIT EN ALPHA-GLUCOSIDASE ACIDE; MALADIE DE POMPE; POMPE DISEASE; POMPE REGISTRY; REGISTRE DE LA MALADIE DE POMPE;

ADULT; AGE DISTRIBUTION; ALPHA-GLUCOSIDASES; BIOPSY; COHORT STUDIES; FEMALE; FRANCE; GLYCOGEN STORAGE DISEASE TYPE II; HUMANS; MALE; MIDDLE AGED; MUSCLES; REGISTRIES;

EID: 84884593948     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurol.2013.07.002     Document Type: Article

References (27)

1. C. Angelini, C. Semplicini, S. Ravaglia, B. Bembi, S. Servidei, and E. Pegoraro Observational clinical study in juvenile-adult glycogenosis type 2 patients undergoing enzyme replacement therapy for up to 4 years J Neurol 259 5 2011 952 958
2. B. Bembi, E. Cerini, C. Danesino, M.A. Donati, S. Gasperini, and L. Morandi Management and treatment of glycogenosis type II Neurology 71 23 Suppl. 2 2008 S12 S36
3. B. Bembi, F.E. Pisa, M. Confalonieri, G. Ciana, A. Fiumara, and R. Parini Long-term observational, non-randomized study of enzyme replacement therapy in late-onset glycogenosis type II J Inherit Metab Dis 33 2010 727 735
4. C. Benaïm, S. Sacconi, M. Fournier-Mehouas, V. Tanant, and C. Desnuelle Validity of the motor function measurement scale when routinely used in the follow-up of adult outpatients in a neuromuscular center Rev Neurol (Paris) 166 2010 49 53
5. C. Bérard, C. Payan, I. Hodgkinson, J. Fermanian MFM Collaborative Study Group A motor function measure for neuromuscular diseases. Construction and validation study Neuromuscul Disord 15 7 2005 463 470
6. C. Bérard, F. Girardot, I. Hodgkinson, C. Payan The MFM Study Group Motor Function Measure User's manual 3rd Ed. 2010 AFM Evry France Lyon [http://www.institut-myologie.org/escale/upload/pdf/Manuel-Utilisateur-MFM.pdf]
7. B.J. Byrne, P.S. Kishnani, L.E. Case, L. Merlini, W. Müller-Felber, and S. Prasad Pompe disease: design, methodology, and early findings from the Pompe Registry Mol Genet Metab 103 1 2011 1 11
8. E.J. Cupler, K.I. Berger, R.T. Leshner, G.I. Wolfe, J.J. Han, and R.J. Barohn Consensus treatment recommendations for late-onset Pompe disease Muscle Nerve 45 3 2012 319 333
9. A.G. Engel Acid maltase deficiency in adults: studies in four cases of a syndrome which may mimic muscular dystrophy or other myopathies Brain 93 3 1970 599 616
10. Y. Furusawa, M. Mori-Yoshimura, T. Yamamoto, C. Sakamoto, M. Wakita, and Y. Kobayashi Effects of enzyme replacement therapy on five patients with advanced late-onset glycogen storage disease type II: a 2-year follow-up study J Inherit Metab Dis 35 2 2012 301 310
11. D. Güngör, J.M. de Vries, W.C. Hop, A.J. Reuser, P.A. van Doorn, and A.T. van der Ploeg Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy Orphanet J Rare Dis 6 2011 34
12. M.L. Hagemans, L.P. Winkel, P.A. Van Doorn, W.J. Hop, M.C. Loonen, and A.J. Reuser Clinical manifestation and natural course of late-onset Pompe disease in 54 Dutch patients Brain 128 Pt 3 2005 671 677
13. P. Kishnani, D. Corzo, M. Nicolino, B. Byrne, H. Mandel, and W.L. Hwu Recombinant human acid α-glucosidase: major clinical benefits in patients with infantile-onset Pompe disease Neurology 68 2007 99 109
14. P.S. Kishnani, D. Corzo, N.D. Leslie, D. Gruskin, A. Van der Ploeg, and J.P. Clancy Early treatment with alglucosidase alfa prolongs long-term survival in infants with Pompe disease Pediatr Res 66 2009 329 335
15. P. Laforêt, M. Nicolino, P.B. Eymard, J.P. Puech, C. Caillaud, and L. Poenaru Juvenile and adult-onset acid maltase deficiency in France: genotype-phenotype correlation Neurology 55 2000 1122 1128
16. P. Laforêt, V. Doppler, C. Caillaud, K. Laloui, K.G. Claeys, and P. Richard Rigid spine syndrome revealing late-onset Pompe disease Neuromuscul Disord 20 2 2010 128 130
17. J.C. Llerena Jr., D.M. Horovitz, S.K. Marie, G. Porta, R. Giugliani, and M.V. Rojas Brazilian Network for Studies in Pompe Disease (ReBrPOM). The Brazilian consensus on the management of Pompe disease J Pediatr 155 4 Suppl. 2009 S47 S56
18. D. Orlikowski, N. Pellegrini, H. Prigent, P. Laforêt, R. Carlier, and P. Carlier Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease Neuromuscul Disord 7 2011 477 482
19. N. Pellegrini, P. Laforêt, D. Orlikowski, M. Pellegrini, C. Caillaud, and B. Eymard Respiratory insufficiency and limb muscle weakness in adults with Pompe's disease Eur Respir J 26 6 2005 1024 1031
20. N. Raben, E. Ralston, Y.S. Chien, R. Baum, C. Schreiner, and W.L. Hwu Differences in the predominance of lysosomal and autophagic pathologies between infants and adults with Pompe disease: implication for therapy Mol Genet Metab 101 2010 324 331
21. C. Regnery, C. Kornblum, F. Hanisch, S. Vielhaber, N. Strigl-Pill, and Grunert B. 36 months observational clinical study of 38 adult Pompe disease patients under alglucosidase alfa enzyme replacement therapy J Inherit Metab Dis 35 5 2012 837 845
22. S. Strothotte, N. Trigl-Pill, B. Grunert, C. Kornblum, K. Eger, and C. Wessig Enzyme replacement therapy with alglucosidase alfa in 44 patients with late-onset glycogen storage disease type 2: 12-month results of an observational clinical trial J Neurol 257 2010 91 97
23. C.I. van Capelle, L.P.F. Winkel, M.L.C. Hagemans, S.K. Shapira, W.F. Arts, and P.A. van Doorn Eight years' experience with enzyme replacement therapy in two children and one adult with Pompe disease Neuromuscular disorder 18 6 2008 447 452
24. C.I. van Capelle, N.A.M.E. van der Beek, M.L.C. Hagemans, W.F. Arts, W.C. Hop, and P. Lee Effect of enzyme therapy in juvenile patients with Pompe disease: a three-year open-label study Neuromuscul Disord 20 12 2010 775 782
25. A.T. van der Ploeg, and A.J. Reuser Pompe's disease Lancet 372 9646 2008 1342 1353
26. A.T. van der Ploeg, P.R. Clemens, D. Corzo, D.M. Escolar, J. Florence, and G.J. Groeneveld A randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease N Engl J Med 362 2010 1396 1406
27. J.H. Wokke, M.G. Ausems, M.J. van den Boogaard, E.F. Ippel, O. van Diggelene, and M.A. Kroos Genotype-phenotype correlation in adult-onset acid maltase deficiency Ann Neurol 38 3 1995 450 454